Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inozyme Pharma Inc. filings document the company’s transition from a Nasdaq-listed clinical-stage biotechnology issuer to an acquired company. The filing record includes Form 8-K material-event disclosures for the completed BioMarin acquisition, related termination of the employee stock purchase plan, and capital-structure matters involving Inozyme common stock.
Subsequent corporate-status filings include Nasdaq’s Form 25 notification removing the common stock from listing and registration and Inozyme’s Form 15 certification to terminate or suspend Exchange Act reporting obligations. Earlier disclosures also cover shareholder voting matters, operating and financial results, governance, and clinical or regulatory information tied to INZ-701 and rare-disease development.
Inozyme Pharma, Inc. (INZY) has submitted a Form 25 to the SEC, signaling the removal of its common stock from listing and registration on the Nasdaq Stock Market under Section 12(b) of the Exchange Act.
The document, signed by Nasdaq AVP Tara Petta on 2025-07-01, states that the exchange has met all procedural requirements of Rule 12d2-2 for striking the security. The filing covers only the company’s common stock and does not disclose the reason for the delisting—whether involuntary (e.g., non-compliance) or voluntary (e.g., merger, alternate listing).
After effectiveness, trading in INZY shares on Nasdaq will cease and the Section 12(b) registration will be withdrawn 10 days later, materially affecting share liquidity, index eligibility, and disclosure obligations. Investors should watch subsequent SEC filings or company announcements for context on trading venue migration (such as OTC) and any strategic ramifications.